Evidence map›Paper›PMID 39420367›Full record

Observational studyCardiovascular diabetology2024

Unseen threat: how subclinical atherosclerosis increases mortality risk in patients with type 1 diabetes.

Lidia Sojo-Vega, Mònica Recasens, Joan Martínez, Alexandre Aguilera, Maria Ayala, Natàlia Admetlla, Paula Pellicer, Cristina Blay, Berta Fabregat, Mariona Esteve-Serra and 12 more

Abstract readObservational Study
In one paragraph

Observational study in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lidia Sojo-VegaDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Mònica RecasensDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Joan MartínezBiomedical Research Institute of Girona (IDIBGI), Carrer del Dr. Castany s/n, 17190, Salt, Spain.
Alexandre AguileraDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Maria AyalaDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Natàlia AdmetllaDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Paula PellicerDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Cristina BlayDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Berta FabregatDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Mariona Esteve-SerraDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Lídia RieraDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Rebeca BarahonaDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Gemma XifraDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Eduardo EsteveDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Josefina BiarnésDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
David PérezDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Gemma GifreDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Sílvia MauriDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Elisabet CostaDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Marzena WosDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain.
Maria BuxóBiomedical Research Institute of Girona (IDIBGI), Carrer del Dr. Castany s/n, 17190, Salt, Spain.
Mercè Fernández-BalsellsDepartment of Endocrinology, Diabetes Unit, University Hospital Dr, Josep Trueta of Girona, Av. França s/n, 17007, Girona, Spain. mercefernandez.girona.ics@gencat.cat.ORCID 0000-0001-8221-4237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD), particularly ischemic heart disease, remains the leading cause of death and morbidity in patients with type 1 diabetes. Detecting subclinical atherosclerosis could enhance cardiovascular risk stratification and enable individualised therapies. The aim of this study is to investigate the prevalence and predictors of subclinical atherosclerosis in patients with type 1 diabetes without overt cardiovascular disease (CVD) and to assess its impact on patient survival over a follow-up period of at least 5 years.

methodsThis observational study included 507 patients treated at the Diabetes Unit of the Hospital of Girona Doctor Josep Trueta between 2015 and 2023. The inclusion criteria for patients were as follows: those aged 18 and older with diabetes for a minimum of 10 years or those aged 40 and older with a diabetes for at least 5 years. Subclinical atherosclerosis was identified via ultrasound imaging of the carotid and femoral arteries. Clinical and biochemical evaluations were also conducted. Major cardiovascular events (MACE) and deaths from other causes were monitored, and survival analysis was performed using Kaplan‒Meier methods.

resultsSubclinical atherosclerosis was detected in 218 patients (43%). Multivariate analysis revealed that the male sex, diabetic nephropathy, tobacco exposure, higher HbA1c levels, older age, and longer diabetes duration were significant predictors. During a mean follow-up of 70.64 ± 27.08 months, 19 patients experienced MACE, and 13 died from any cause. The probability of MACE or death was greater in patients with subclinical atherosclerosis, with a hazard ratio (HR) of 25.1 (95% CI 5.81-108, p < 0.001) for MACE and an odds ratio (OR) of 7.57 (95% CI 1.97-53.9, p = 0.004) for death.

conclusionSubclinical atherosclerosis is independently associated with increased overall mortality and MACE in patients with type 1 diabetes. Identifying clinical predictors can improve risk stratification and personalised therapeutic strategies to prevent MACEs in this high-risk population.

Indexed as

Asymptomatic DiseasesDiabetes Mellitus, Type 1AdultAgedAtherosclerosisBiomarkersCarotid Artery DiseasesCause of DeathFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPrevalencePrognosisRisk AssessmentBiomarkersCardiovascular disease mortalitySubclinical atherosclerosisType 1 diabetes

Identifiers

PMID39420367
PMCPMC11488122

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.